This phase II study was conducted to determine the efficacy and safety of metronomic temozolomide (TMZ) in combination with irinotecan in glioblastoma (GB) at first relapse. Patients with GB at first relapse received TMZ 50 mg/m 2 /day divided into three doses, except for a single 100 mg/m 2 dose, administered between 3 and 6 h before every irinotecan infusion. Irinotecan was given intravenously at the previously established dose of 100 mg/m 2 on days 8 and 22 of 28-day cycles. Treatment was given for a maximum of nine cycles or until progression or unacceptable toxicity occurred. Vascular endothelial growth factor and its soluble receptor 1, thrombospondin-1, microparticles, and microparticle-dependent procoagulant activity were measured in blood before treatment. The primary objective was 6-month progression-free survival (PFS). Twenty-seven evaluable patients were enrolled. Six-month PFS was 20.8%. Median PFS was 11.6 weeks (95% confidence interval: 7.5-15.7). Stable disease was the best response for nine (37.5%) patients, with a median duration of 11.2 weeks (4.2-35.85 weeks). No differences in PFS or response were observed among patients who relapsed during or after completion of adjuvant TMZ. Grade 3/4 adverse events included lymphopenia (15%), fatigue, diarrhea and febrile neutropenia (3.7% each), lymphopenia, neutropenia, and nausea/vomiting (11.1% each). One patient died from pneumonia and one patient died from pulmonary thromboembolism. Pretreatment levels of angiogenesis biomarkers, microparticles, and microparticle-related procoagulant activity were elevated in patients compared with healthy volunteers. This regimen is feasible, but failed to improve the results obtained with other second-line therapies in recurrent GB.
Introduction
The prognosis of glioblastoma (GB) remains poor. Standard therapy with surgery followed by radiation therapy and temozolomide (TMZ) provides a median progression-free survival (PFS) of around 7 months and a median overall survival of less than 15 months [1] , although it varies according to the methylation status of the O6-alkylguanine-DNA-methyltransferase (MGMT) gene promoter [2] . Therefore, treatment of recurrent disease remains an important goal.
Treatment options for recurrent disease are limited [3] , making obvious the need to explore new therapeutic strategies. Several studies have been carried out using dose-dense, extended TMZ, including treatment for 21 days every 28 days or every other week [4, 5] . In 2008, Perry et al. [6] reported the preliminary results of TMZ at a continuous dose of 50 mg/m 2 in patients with recurrent GB. Patients were stratified into three groups, according to timing of recurrence related to the period of adjuvant TMZ. In the final report [7] , 6-month PFS was 7.4% for patients who progressed while receiving adjuvant TMZ beyond six cycles, and 35.7% for patients who progressed after completion of adjuvant TMZ with a treatment-free interval more than 2 months.
Irinotecan has demonstrated clinical activity in recurrent GB, reaching 15% objective response in one study [8] . TMZ and irinotecan exert antitumoral activity through different mechanisms and have different toxicity profiles. Furthermore, preclinical data have demonstrated that the combination of TMZ and irinotecan has a synergistic and schedule-dependent antitumor activity [9] . Moreover, the cytotoxic effect of this combination seems to be independent of the methylation status of the MGMT gene promoter [10] . We recently carried out a phase I trial designed to find the maximum tolerated dose of irinotecan given every 2 weeks, combined with a fixed and continuous dose of TMZ, in patients with GB at first relapse [11] . We now report a phase II, multicenter clinical trial conducted by the Spanish Neuro-Oncology Research Group (Grupo Español de Investigación en Neurooncología, GEINO). The trial was designed to determine the efficacy and toxicity of this treatment schedule.
The primary objective of the study was to determine the PFS rate at 6 months. Secondary objectives included response rate and toxicity. Moreover, the study sought to evaluate the influence of plasma concentration of thrombospondin-1 (TSP-1), vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor 1 (sVEGFR-1), and microparticles (MPs) on clinical outcome.
Patients and methods

Eligibility
To enter the study, patients were required to be at least 18 years old, have a Karnofsky Performance Status (KPS) score 70 or more, and a histologically confirmed GB at first recurrence. Initial standard treatment [1] with radiotherapy and concomitant TMZ, followed by a minimum of three cycles of adjuvant TMZ, was also mandatory. The diagnosis of recurrence was established by an MRI performed within 3 weeks before starting treatment, according to Macdonald's criteria [12] . Additional requirements included adequate bone marrow and renal and hepatic function, as previously described [11] .
Patients were excluded if they were pregnant or breastfeeding, and if they had other malignancies, except basal cell carcinoma or cervical carcinoma in situ. Simultaneous treatment with drugs having a potent inhibitory or inducing activity on cytochrome P450 (CYP450) enzymes was not permitted. Enzymeinducing antiepileptic drugs had to be replaced by non-enzyme-inducing antiepileptic drugs, at least 1 week before starting the protocol treatment. The study was approved by the ethics committees of the participating centers. To have a normal reference of circulating biomarkers, a control group was included. The control group was composed of healthy individuals from the same demographic area, whose age and sex matched those of the patients. Informed consent was obtained from all patients and healthy volunteers.
Study design and treatment plan
All patients received oral TMZ at a fixed and continuous dose of 50 mg/m 2 divided into three daily intakes, except for a single 100 mg/m 2 dose, administered between 3 and 6 h before every irinotecan infusion. The calculated dose was rounded to the nearest 5 mg. Irinotecan was given intravenously at the previously established dose of 100 mg/m 2 on days 8 and 22 of 28-day cycles. Antiemetic drugs, preferably metoclopramide, were allowed in case of nausea or vomiting. Oral serotonin antagonists were permitted when necessary. Before every irinotecan infusion 0.25 mg subcutaneous atropine and an intravenous serotonin antagonist were administered. Prophylactic administration of granulocyte-colony stimulating factors was not allowed. Erythropoietin and red blood cell or platelet transfusions could be administered. Treatment was given for a maximum of nine cycles or until progression or unacceptable toxicity occurred.
Surveillance and follow-up
Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria, Version 3.0. The baseline examinations were performed within 3 weeks before the start of treatment and included complete blood count, serum biochemistry profile (SBP), blood sampling for assessment of circulating biomarkers, brain MRI, physical examination, KPS, Barthel Index, and chest radiograph. Evaluation of complete blood count, SBP, and KPS, as well as assessment of toxicity, was repeated on days 8 and 22 of every treatment cycle. An SBP was repeated on day 8 of every cycle. A brain MRI and a Barthel Index were performed on day 8 of odd cycles, as from the third cycle. Dose delays, reductions, and discontinuations were applied according to the protocol, and have been detailed elsewhere [11] . Objective responses were assessed following Macdonald's criteria [12] .
Blood sampling
For the determination of MP levels and MP-mediated procoagulant activity, blood was collected in a BD Vacutainer tube (BD, Franklin Lakes, New Jersey, USA) containing sodium citrate (129 mmol/l) at a ratio of 1 : 9 (v/v, sodium citrate/blood) and in dry BD Vacutainer tubes for the determination of angiogenic biomarkers. After 30-90 min, blood samples were centrifuged at 1500g for 15 min at room temperature to obtain plasma or serum, which was divided into 200 µl aliquots and stored at − 80°C for later batch analysis.
Biomarker analysis
Total serum levels of VEGF and sVEGFR-1 were determined by ELISA according to the manufacturers' instructions [VEGF (Biosource International, Camarillo, California, USA) and Quantikine Human sVEGFR1 (R&D Systems, Minneapolis, Minnesota, USA)]; the coefficients of variation were 6.5 and 7.0%, respectively. TSP-1 levels were quantified by an indirect ELISA, as described elsewhere [13] ; the coefficient of variation was 4.8%.
Plasma MPs were quantified by flow cytometry in an EPICS XL Cytometer (Beckman Coulter, Brea, California, USA) at high flow rate. Plasma was incubated with FITC-Annexin V conjugate (TACS Annexin V; Trevigen Inc., Gaithersburg, Maryland, USA) to detect accessible phosphatidylserine on MP membranes, as previously described [14] .
The MP-mediated procoagulant activity of plasma was analyzed by thrombin generation assay without added exogenous tissue factor or phospholipids (Calibrated Automated Thrombogram; Thrombinoscope BV, Paris, France), as previously described [15] .
Statistical analysis
Among patients with recurrent GB treated with extended-dose TMZ, 6-month PFS varies widely, reaching 20% or more in most studies. The present study was initially designed to include 50 patients, assuming a 6-month PFS of 22% with a 95% confidence interval (CI) between 10.5 and 33.5%. Nevertheless, because of low recruitment, the protocol was modified to reduce the number of patients. On the basis of published data of dose-extended TMZ [4] , a 6-month PFS of 30% was considered achievable; therefore, an amendment to the protocol was approved to reduce the number of patients to 30, resulting in a 95% CI between 13.6 and 46.4% for an estimated 6-month PFS of 30%.
PFS was analyzed by the Kaplan-Meier method. Results are given as mean SD for continuous variables. The Kolmogorov-Smirnov test was used to evaluate whether each parameter came from a normal distribution. The Mann-Whitney U-test was conducted to analyze the independent relationship of healthy individuals with patients. Bivariated correlation was performed using the Spearman correlation test. All statistical calculations were performed using SPSS software (v.15.0; SPSS Inc., Chicago, Illinois, USA). P values less than 0.05 were considered statistically significant.
Results
Patient recruitment and demographics
A total of 30 patients from eight centers were initially enrolled. Three patients had been included in the previous phase I trial and had received the dose of irinotecan selected for the phase II trialthat is, 100 mg/m 2 . The remaining patients were recruited over 16 months. Patient flow is depicted in Fig. 1 . Three patients were excluded from the study: in one the diagnosis of GB was not confirmed; another patient did not meet all inclusion criteria; and the other did not start treatment after signing the informed consent form. Clinical patient characteristics are shown in Table 1 .
Progression-free survival
Twenty-seven patients started treatment. At 6 months, five (20.8%) patients remained progression free. Median PFS was 11.6 weeks (95% CI: 7.5-15.7) (Fig. 2) .
Response
Twenty-four patients were evaluable for response. No partial or complete responses were observed. Stable disease was the best response in nine (37.5%) patients, with a median duration of 11.2 weeks (4.2-35.85 weeks). No differences in PFS or response were observed among patients who relapsed during or after completion of adjuvant TMZ.
Toxicity
All 27 patients were assessable for toxicity. One patient died from pneumonia on day 16 of the first cycle. Another patient died on cycle 3 after an episode of acute dyspnea clinically compatible with pulmonary thromboembolism. Died before evaluation (n = 2) Not evaluated (n = 1)
GB not confirmed (n = 1) Inclusion criteria not met (n = 1) Did not start treatment (n = 1)
Patient flow. GB, glioblastoma; PFS, progression-free survival. Temozolomide/irinotecan in glioblastoma Reynés et al. 135 No opportunistic infections were observed. Table 2 shows all grades of toxicity registered. Table 3 summarizes the levels of the angiogenesis markers (VEGF, VEGFR-1, TSP-1) and MPs in patients before the start of the study treatment, and in controls. Among the angiogenesis markers, VEGF levels (P < 0.05) and VEGFR-1 levels (P < 0.001) were significantly elevated in patients. Levels of MPs and their procoagulant activity were also higher in patients than in controls. No correlations have been found among the biomarkers studied. Moreover, no associations were found between marker levels and clinical outcome.
Circulating marker levels
Discussion
The rationale for this phase II study was the synergistic effect of TMZ and irinotecan that could result in improved results compared with other continuous-dose TMZ schedules. Nevertheless, although the 6-month PFS reached in the present study is superior to that reported in some phase II studies with dose-dense TMZ [16, 17] , it was not superior to other regimens used for the treatment of recurrent GB. The primary objective of the study, 6-month PFS, was 20.8%, and the median PFS was 10.4 weeks. In a review article [18] , rechallenge with TMZ has been analyzed in two different settings: in patients experiencing progressive disease during TMZ therapy who were rechallenged with alternative TMZ regimens, and in patients rechallenged after a TMZ-free interval of at least 8 weeks. PFS-6 rates were 27.7 and 28.6%, respectively. Second-line treatment with the nitrosourea fotemustine has yielded 6-month PFS rates between 35 and 39%, even in elderly patients [19, 20] . In a phase II study [21] , bevacizumab has been used in monotherapy and in combination with irinotecan; reported 6-month PFS was 43 and 50%, respectively, although these results should be interpreted cautiously, given the difficulty of assessing response to antiangiogenic drugs.
In another phase II study [22] , monotherapy with bevacizumab resulted in a 6-month PFS of 29%.
Interestingly, grade 3 and 4 lymphopenia, a characteristic hematologic toxicity of metronomic TMZ regimens [23] , has been registered in less than 20% of patients, and no opportunistic infections occurred, despite the lack of specific prophylaxis. However, two patients died because of adverse events (one from pneumonia and another one from a likely pulmonary thromboembolism), raising doubts about the safety of treatment.
Metronomic chemotherapy exerts antiangiogenic effect through different mechanisms [24] . Several studies in vitro and in vivo have shown that metronomic TMZ inhibited proliferation, adhesion, and migration of glioma-associated endothelial cells and human umbilical vein endothelial cells [25] [26] [27] , and inhibited MGMT expression in human umbilical vein endothelial cell [26] compared with conventional TMZ dosing. Nevertheless, Virrey et al. [28] , using different assays in vitro and in vivo, Data are presented as mean SD. MP, microparticle; TG, endogen thrombin generation; TSP-1, thrombospondin-1; VEGF, vascular endothelial growth factor; VEGFR-1, vascular endothelial growth factor receptor 1. observed no effect of TMZ on proliferation or migration of glioma-associated endothelial cells.
Consistent with previous results in newly diagnosed patients with GB [29] , VEGF and VEGFR-1, but not TSP-1, were elevated in this series of patients at first relapse. MP levels and MP-related procoagulant activity were also elevated. We had previously observed increased numbers of MPs in patients with GB after surgery, before starting radiation therapy and TMZ [15] . Nevertheless, none of these markers showed associations with clinical outcome.
In summary, this regimen of irinotecan and metronomic TMZ was well tolerated, but failed to improve significantly the results obtained with other second-line therapies in recurrent GB.
